Burning Rock Biotech Reports Q1 GAAP EPS of -$0.02, Revenue of $18.34M

Burning Rock Biotech reported Q1 GAAP EPS of -$0.02 and revenue of $18.34M, a 5.9% Y/Y increase. The company's revenues were RMB133.1 million ($18.3 million) for the three months ended March 31, 2025.

Burning Rock Biotech Limited (NASDAQ: BNR), a precision oncology company, has reported its financial results for the first quarter of 2025. The company reported a GAAP EPS of -$0.02 and revenues of RMB133.1 million (US$18.3 million), representing a 5.9% year-over-year increase [1].

Revenue growth was driven by a 79.9% increase in pharma research and development services, which generated RMB37.1 million (US$5.1 million) for the quarter, up from RMB20.6 million in the same period of 2024 [2]. The central laboratory business, however, saw a 19.6% decrease in revenue, primarily due to a decrease in the number of tests [2].

Operating expenses decreased by 46.8% to RMB112.6 million (US$15.5 million), driven by budget control measures and headcount reduction [2]. Gross profit increased by 13.7% year-over-year to RMB97.4 million (US$13.4 million), with a gross margin of 73.2% [2].

Despite the net loss of RMB13.5 million (US$1.9 million), the company reported a cash position of RMB497.4 million (US$68.5 million) as of March 31, 2025 [2]. The company also highlighted significant advances in its oncology treatments, including the CanCatch® Custom MRD product for esophageal squamous cell carcinoma and the MUSETALK-Lung01 study for early-stage NSCLC patients [2].

References:
[1] https://seekingalpha.com/news/4456127-burning-rock-biotech-gaap-eps-of-0_02-revenue-of-18_34m
[2] https://www.nasdaq.com/articles/burning-rock-biotech-limited-reports-q1-2025-financial-results-and-advances-oncology